Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 800

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 800
---
 ​            
 ​            
 Common Stock 
 Shares       | ​ 
 ​ | ​ 
 ​ | ​ 
 ​ |         ​ 
         ​ 
         ​ | ​ 
 ​ 
 ​ | ​      
 ​      
 Amount | ​ 
 ​ | ​ 
 ​ | ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | ​ | ​ | ​ | AdditionalPaid-InCapital |   |         |   | ​ | ​ | AccumulatedDeficit |   |          |   | ​ | ​ | AccumulatedOtherComprehensiveIncome (Loss) |   |        |   | ​ | ​ | TotalStockholders’Equity |   |          |   | ​ |
|:----------------------------------------------------------------------------------------|:-------------|:--|:--|:--|----------:|:--|:-------|:--|:--|:--|--:|:--|:--|:--|:-------------------------|:--|--------:|:--|:--|:--|:-------------------|:--|---------:|:--|:--|:--|:-------------------------------------------|:--|-------:|:--|:--|:--|:-------------------------|:--|---------:|:--|:--|
| Balance at December 31, 2020                                                            | ​            | ​ | ​ | ​ | 4,156,017 | ​ | ​      | ​ | ​ | $ | 4 | ​ | ​ | ​ | ​                        | $ | 641,241 | ​ | ​ | ​ | ​                  | $ | -392,317 | ​ | ​ | ​ | ​                                          | $ |     73 | ​ | ​ | ​ | ​                        | $ |  249,001 | ​ | ​ |
| Sale of common stock under licenseagreement with Vifor International($182.76 per share) | ​            | ​ | ​ | ​ |   273,533 | ​ | ​      | ​ | ​ | ​ | — | ​ | ​ | ​ | ​                        | ​ |  44,966 | ​ | ​ | ​ | ​                  | ​ |        — | ​ | ​ | ​ | ​                                          | ​ |      — | ​ | ​ | ​ | ​                        | ​ |   44,969 | ​ | ​ |
| Stock-based compensationexpense                                                         | ​            | ​ | ​ | ​ |         — | ​ | ​      | ​ | ​ | ​ | — | ​